Pharmacogenomics of Sorafenib in Hepatocellular Carcinoma (HCC): A LncRNA-Expression Guided Approach Using UCA1 and MALAT1 for Personalizing Therapy in a 154-Patient Cohort.

ABSTRACT: Background/Objectives: Hepatocellular carcinoma (HCC) presents limited therapeutic options for advanced disease, and sorafenib therapy is hampered by significant interpatient heterogeneity in response. This necessitates biomarker-guided strategies to personalize treatment. This study investigated the long noncoding RNAs UCA1 and MALAT1 as pharmacogenomic biomarkers for personalizing sorafenib therapy in advanced HCC. Methods: In a prospective cohort of 154 HCC patients receiving first-line sorafenib (400 mg twice daily), serum lncRNA levels were quantified by RT-qPCR at baseline, Week 4, and Week 12. Expression levels were correlated with treatment response (mRECIST), time-to-progression (TTP), and overall survival (OS). Statistical analyses included Kaplan-Meier estimates, C

SUBMITTER: Nazih M 

PROVIDER: S-EPMC12844796 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature